CN102847095A - Pharmaceutical composition for treating diabetes - Google Patents
Pharmaceutical composition for treating diabetes Download PDFInfo
- Publication number
- CN102847095A CN102847095A CN2011101842408A CN201110184240A CN102847095A CN 102847095 A CN102847095 A CN 102847095A CN 2011101842408 A CN2011101842408 A CN 2011101842408A CN 201110184240 A CN201110184240 A CN 201110184240A CN 102847095 A CN102847095 A CN 102847095A
- Authority
- CN
- China
- Prior art keywords
- group
- rhizoma
- medicine
- diabetes
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating diabetes. The active ingredients of the pharmaceutical composition comprise (by weight parts) Momordica charantia 25-35, Rhizoma Coptidis 25-35, Monas cuspurpureus 2-4, processed Zingiber officinale and Radix Et Rhizoma Rhei 1-3. The pharmaceutical composition can reduce insulin resistance and restore the functions of the islet cells to greatly improve abnormal glucose metabolism, is significant in relieving fatty liver and maintaining normal blood lipid level, and is clinically used for the treatment of diabetes.
Description
Technical field
The invention belongs to the field of Chinese medicines, specifically relate to a kind of medicine for the treatment of diabetes.
Background technology
Diabetes (diabetes) are to act on that body causes hypoinsulinism, insulin resistant etc. and a series of metabolism disorder syndromes such as the sugar that causes, protein, fat, power and water Xie Zhi by inherited genetic factors, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, Nervous and Mental Factors etc. various virulence factors, clinically take hyperglycemia as main feature, the performance such as polyuria, polydipsia, polyphagia can appear in model case, become thin.
Diabetes are divided type 1 diabetes and type 2 diabetes mellitus.In diabetics, the shared ratio of type 2 diabetes mellitus is about 95%.
Type 2 diabetes mellitus sugar, disorders of lipid metabolism are an integral body, the two connects each other, influence each other, therefore in treatment, to consider from the organic conception of disease comprehensively, avoid independent blood sugar lowering or lipid-lowering therapy, affect the treatment, must be placed on status of equal importance to blood sugar lowering, accent fat, this will be conducive to the control to type 2 diabetes mellitus, hyperlipemia, atherosclerosis, thereby reach the purpose of Comprehensive Control type 2 diabetes mellitus.
Chinese patent application (publication number 101204573) discloses a kind of medicine for the treatment of diabetes.This medicine is to be made by the raw material of following weight: Fructus Momordicae charantiae slice, Radix Sophorae Flavescentis, Rhizoma Coptidis, the Rhizoma Anemarrhenae, Semen Ziziphi Spinosae, Rhizoma Zingiberis Preparatum, Monas cuspurpureus Went, Pericarpium Citri Reticulatae, Radix Et Rhizoma Rhei, Semen Persicae.Can obviously improve by the improvement of insulin resistant and islet cell function the abnormal carbohydrate metabolism of type 2 diabetes mellitus rat model, significant to alleviating fatty liver and keeping normal lipid.
But because the flavour of a drug in this invention prescription are on the high side, dose is larger when making preparation, is difficult to take, and patient's compliance is relatively poor during long-term taking, thereby affects the treatment.
In addition, Chinese patent application (publication number 101085079) discloses a kind of compound Chinese medicinal preparation with treatment diabetes, and it is comprised of Chinese Drug Rhizomes of Coptis 1-6 weight portion, Fructus Momordicae charantiae 1-20 weight portion, Fructus Gardeniae 0-3 weight portion, has heat clearing and damp drying, pathogenic fire purging clears away heart-fire, the effect that relieving restlessness is quenched one's thirst.Can be applicable to clinically the diabetes blood sugar lowering, blood fat reducing, the polydipsia that alleviates diabetes, polyphagia, polyuria, tired, the disease such as become thin, and can share with other antidiabetic drugs, obviously improve hypoglycemic effect.
Summary of the invention
The object of the invention is to by the medicine side of tearing open the research to Chinese patent application (publication number 101204573) invention, it is few to filter out flavour of a drug, and dose is few, eutherapeutic Remedies for diabetes.
Chinese medicine compound is advantage and the characteristic of Chinese traditional treatment, and the Traditional Chinese Medicine treatment thinks that the curative effect of Chinese medicine compound is better than single medicinal material.Yet no matter from chemistry or from pharmacological angle, Chinese medicine compound is all too complicated, and a lot of problems are difficult to illustrate, and are also very limited to the understanding of Chinese medicine compound composition principle and compatibility theory from the angle of modern medicine.And the side of tearing open is the important means of Study of Traditional Chinese Medicine compound recipe prescription, and the at present side's of tearing open research main thought can be summarized as the following aspects: take theory of Chinese medical science as guidance, press the Chinese prescription principle, according to the side's of tearing open the research of herbal nature theory; Study from effective site or composition angle; The applied mathematics pattern instructs the side's of tearing open research.Certainly, above-mentioned theory all need to could be used realization in practice based on the experience accumulation of research worker with in conjunction with a large amount of experiments.The present invention adopts the first thinking according to the side's of tearing open the research of herbal nature theory, as investigating according to the main flavour of a drug or the component that filter out for a certain drug effect, prescription is simplified with pharmacodynamic index, and drug effect is more clear and definite, and taking dose reduces.
The technical scheme that realizes above-mentioned purpose is as follows:
A kind of medicine for the treatment of diabetes, its active ingredient are that the crude drug by following weight parts is prepared from: Fructus Momordicae charantiae 25-35 part, Rhizoma Coptidis 25-35 part, Monas cuspurpureus Went 2-4 part, Rhizoma Zingiberis Preparatum 4-8 part, Radix Et Rhizoma Rhei 1-3 part.
Medicament selection Fructus Momordicae charantiae of the present invention, Rhizoma Coptidis, Monas cuspurpureus Went, Rhizoma Zingiberis Preparatum and Radix Et Rhizoma Rhei make up, so that each efficacy of drugs produces synergism, thereby can effectively treat diabetes.Rhizoma Coptidis, Fructus Momordicae charantiae bitter cold in the side, specially clearing away stomach-heat; Radix Et Rhizoma Rhei specially enters large intestine channel, and eliminating heat pathogen by purging the bowels is removed stagnant in the intestinal, burning hot; Rhizoma Zingiberis Preparatum is hot, closes Rhizoma Coptidis, Fructus Momordicae charantiae, the Radix Et Rhizoma Rhei of bitter cold, and the usefulness of pungent drugs can disperse and bitter drugs can descend is arranged; Food stagnation is cleared up in the Monas cuspurpureus Went fat reducing that helps digestion; All medicines share, Clearing heat and removing obstruction of fu-organs, pungent drugs can disperse and bitter drugs can descend.
Preferably, the medicine of described treatment diabetes, its active ingredient are that crude drug by following weight parts is prepared from: 30 parts in Fructus Momordicae charantiae, 30 parts of Rhizoma Coptidis, 3 parts in Monas cuspurpureus Went, 6 parts of Rhizoma Zingiberis Preparatums, 2 parts of Radix Et Rhizoma Rhei.
For making medicine have better mouthfeel, also can contain the correctives of 1-2 ratio of weight and number in the described medicine.
Medicine provided by the present invention can adopt the conventional method in this area to make, and for example decocting, water decoction-alcohol sedimentation or mill medicated powder are taken after mixing it with water and all can.For taking convenience, medicine provided by the present invention can adopt decoction, electuary, powder, pill, capsule or oral liquid.
Drug usage consumption provided by the present invention is: be grown up 57-85g/ time, decoct with water to 200ml, minutes 2 times oral, and the child is cut down according to the circumstance.
Drug usage dosage optimization provided by the present invention is: be grown up 71g/ time, decoct with water to 200ml, minutes 2 times oral, and the child is cut down according to the circumstance.
When making preparation, its dose is in the crude drug amount: adult's 57-85g/ day, minutes 3 times oral, and the child is cut down according to the circumstance.
The purport of medicine provided by the present invention is the treatment type 2 diabetes mellitus, has following function and curative effect: blood sugar lowering, glycolated hemoglobin, blood fat, improve insulin sensitivity, and improve the secretory function of beta Cell of islet, alleviate fatty liver.Rhizoma Coptidis, Fructus Momordicae charantiae bitter cold in the side, specially clearing away stomach-heat; Radix Et Rhizoma Rhei specially enters large intestine channel, and eliminating heat pathogen by purging the bowels is removed stagnant in the intestinal, burning hot; Rhizoma Zingiberis Preparatum is hot, closes Rhizoma Coptidis, Fructus Momordicae charantiae, the Radix Et Rhizoma Rhei of bitter cold, and the usefulness of pungent drugs can disperse and bitter drugs can descend is arranged; Food stagnation is cleared up in the Monas cuspurpureus Went fat reducing that helps digestion; All medicines share, Clearing heat and removing obstruction of fu-organs, and pungent drugs can disperse and bitter drugs can descend, picric acid system is sweet.
Good effect of the present invention is: preparation is that pure Chinese herbal medicine is made, toxic and side effects is little, by the side's of tearing open screening study, greatly reduced the dose of medicine, and the heat clearing away the turbid descending side of curative effect and Chinese patent application (publication number 101204573) is suitable, is better than the described pharmaceutical composition of Chinese patent application (publication number 101085079).
Description of drawings
Fig. 1: Normal group insulin immunohistochemical staining figure;
Fig. 2: model group insulin immunohistochemical staining figure;
Fig. 3: core side group insulin immunohistochemical staining figure;
Fig. 4: blank group pancreas ultrastructure figure;
Fig. 5: model group pancreas ultrastructure figure;
Fig. 6: core side group pancreas ultrastructure figure.
The specific embodiment
Further set forth the preparation method of medicine of the present invention below by embodiment.
The medicine of the described treatment diabetes of present embodiment, its active ingredient are that the crude drug by following weight parts is prepared from: Fructus Momordicae charantiae 30g, Rhizoma Coptidis 30g, Monas cuspurpureus Went 3g, Rhizoma Zingiberis Preparatum 6g, Radix Et Rhizoma Rhei 2g.
1, the above-mentioned raw materials medicine is put in the medicine pot;
2, add water 500ml (not being advisable to have medicine), soaked 30-40 minute;
3, the moderate heat decocting is 30 minutes, and extracting juice 200ml is oral.
Embodiment 2
The medicine of the described treatment diabetes of present embodiment, its active ingredient are that the crude drug by following weight parts is prepared from: 25 parts in Fructus Momordicae charantiae, 25 parts of Rhizoma Coptidis, 4 parts in Monas cuspurpureus Went, 4 parts of Rhizoma Zingiberis Preparatums, 1 part of Radix Et Rhizoma Rhei.
Preparation method: get the decocting that Fructus Momordicae charantiae, Rhizoma Coptidis, Monas cuspurpureus Went, Rhizoma Zingiberis Preparatum, Radix Et Rhizoma Rhei add respectively 10 times of amounts and boil 2 times, decocted 2 hours for the first time, decocted 1 hour for the 2nd time, the extracting solution that merges secondary, filter, filtrate decompression is concentrated into spray drying behind the thick paste, obtains the extract spray powder.It is an amount of to get extract medicated powder adding dextrin, and the alcoholic solution with 60～90% behind the mixing is granulated, drying, and granulate, sterilization packaging is made electuary.
Embodiment 3
The medicine of the described treatment diabetes of present embodiment, its active ingredient are that the crude drug by following weight parts is prepared from: Rhizoma Coptidis 30g, Fructus Momordicae charantiae 30g, Rhizoma Zingiberis Preparatum 6g, Monas cuspurpureus Went 3g, Radix Et Rhizoma Rhei 2g.
Preparation method: get the decocting that Fructus Momordicae charantiae, Rhizoma Coptidis, Monas cuspurpureus Went, Rhizoma Zingiberis Preparatum, Radix Et Rhizoma Rhei add respectively 10 times of amounts and boil 2 times, decocted 2 hours for the first time, decocted 1 hour for the 2nd time, the extracting solution that merges secondary, filter, filtrate decompression is concentrated into spray drying behind the thick paste, obtains the extract spray powder.It is an amount of to get extract medicated powder adding sodium carboxymethyl cellulose, and the alcoholic solution with 60～90% behind the mixing is granulated, drying, and granulate, capsule is made in filling.
Embodiment 4
The medicine of the described treatment diabetes of present embodiment, its active ingredient are that the crude drug by following weight parts is prepared from: Fructus Momordicae charantiae 35g, Rhizoma Coptidis 35g, Monas cuspurpureus Went 4g, Rhizoma Zingiberis Preparatum 8g, Radix Et Rhizoma Rhei 3g.
Preparation method: get the decocting that Fructus Momordicae charantiae, Rhizoma Coptidis, Monas cuspurpureus Went, Rhizoma Zingiberis Preparatum, Radix Et Rhizoma Rhei add respectively 10 times of amounts and boil 2 times, decocted 2 hours for the first time, decocted 1 hour for the 2nd time, the extracting solution that merges secondary filters, and filtrate decompression is concentrated into 1.0～1.2g raw medicinal herbs/ml, add an amount of sodium benzoate antiseptic, embedding, oral liquid is made in sterilization.
Embodiment 5
Below the curative effect of medication for the treatment of diabetes of the present invention is described further.
1 experimental T2DM rat model modeling method
After 160 wistar rat adaptabilities are fed a week, be divided at random 2 groups by body weight, 10 blank groups are raised with normal diet.Other 150 are given high lipid food and fat milk gavage (after 1ml/100g body weight/d) fed for 8 weeks, (be made into 1% solution in 0.1mol/L citrate buffer solution ice bath through tail vein injection STZ, pH4.4) 30mg/kg, modeling, the isopyknic citric acid-sodium citrate buffer of blank group tail vein injection.Measure the random blood sugar value after 1 week, glycemic peaks＞16.7mmol/L thinks that modeling is successful.Then according to blood glucose and body weight hierarchical grouping, begin gastric infusion.
Fat milk prescription: Adeps Sus domestica 20g, propylthiouracil 1g, cholesterol 8g, sodium glutamate 1g, sucrose 5g, fructose 5g, Tween 80 15mL, propylene glycol 15mL, water 35mL.
The fat milk method for making: 70 ℃ of water-baths of Adeps Sus domestica are melted, and are incubated for subsequent use; The propylthiouracil porphyrize adds cholesterol and propylene glycol, and 25000rpm homogenizing 2min without visible particle, is incubated for subsequent use; Sodium glutamate 1g, sucrose 5g, fructose 5g water dissolution adds Tween 80 in the stirring, stirs, 60 ℃ of heating in water bath, 3000-4000rpm slowly adds oil phase under stirring, stirs, both.
2, grouping and administration
Experimental T2DM rat animal model is looked after body weight and is divided at random 11 groups, 12 every group according to the blood glucose value layering.Each group amounts to 12 weeks of administration according to the dosage gastric infusion of drafting, and totally 84 days, dosage 0.5mL/100g body weight * days.Each group of Chinese medicine takes by weighing medicine by prescription, adds suitable quantity of water (not being advisable to have medicine) and decocts, and is concentrated into appropriate volume, and wherein the clearing away heat-fire group is the extracting method preparation of 101085079 Chinese patent application by publication number; The extract group is pressed crude drug amount and extraction ratio conversion, is made into respective volume with normal saline.
(1) blank group: not modeling gives the equivalent normal saline;
(2) model group: give the equivalent normal saline;
(3) metformin group: 200mg/kg/d;
(4) rosiglitazone group: 0.3mg/kg/d;
(5) full side's group (publication number is the Chinese patent application of CN101204573 side commonly used): Rhizoma Coptidis 30g, Fructus Momordicae charantiae 30g, Radix Sophorae Flavescentis 9g, Rhizoma Anemarrhenae 30g, Semen Ziziphi Spinosae 15g, Rhizoma Zingiberis Preparatum 6g, Monas cuspurpureus Went 3g, Pericarpium Citri Reticulatae 9g, Radix Et Rhizoma Rhei 2g, Semen Persicae 6g;
(6) core side's group (embodiment 3): Rhizoma Coptidis 30g, Fructus Momordicae charantiae 30g, Rhizoma Zingiberis Preparatum 6g, Monas cuspurpureus Went 3g, Radix Et Rhizoma Rhei 2g;
(7) bitter cold group: Rhizoma Coptidis 30g, Fructus Momordicae charantiae 30g, Radix Sophorae Flavescentis 9g, Rhizoma Anemarrhenae 30g;
(8) bitter cold core group: Rhizoma Coptidis 30g, Fructus Momordicae charantiae 30g;
(9) clearing away heat-fire group (publication number is the Chinese patent application prescription of CN101085079A, and prepares by its extracting method): Rhizoma Coptidis 30g, Fructus Momordicae charantiae 30g, Fructus Gardeniae 10g;
(10) Clearing heat and removing obstruction of fu-organs group: Rhizoma Coptidis 30g, Fructus Momordicae charantiae 30g, Radix Et Rhizoma Rhei 2g, Monas cuspurpureus Went 3g;
(11) pungent drugs can disperse and bitter drugs can descend group: Rhizoma Coptidis 30g, Fructus Momordicae charantiae 30g, Monas cuspurpureus Went 3g, Rhizoma Zingiberis Preparatum 6g.
The grouping situation sees Table 1:
Table 1: experimental T2DM rat model is by body weight and blood glucose grouped table
Annotate: * represents to compare with model group P＜0.05, and * * represents to compare with model group P＜0.01.
By table 1 data as seen, each component group of model is even, and each organizes blood glucose and body weight approaches, there was no significant difference.
3 results
3.1 ordinary circumstance
The rats in normal control group mental status is good, is quick on the draw, and moves freely, and fur is glossy, the model group rat between the high lipid food feed, behind the injection STZ, lethargy, bradykinesia, slow movement, fur is matt, Mortality.Each treatment group is improved in various degree, wherein full side group, core side's group, bitter cold core group and bitter cold group improve aspect the laboratory animal ordinary circumstance comparatively obvious.
3.2 body weight change situation
Descend gradually unknown significance difference between each treatment group group after the modeling behind the laboratory animal body weight rising.
3.3. change of blood sugar situation
Each group is measured random blood sugars respectively at 0,4,6,8,12 weeks behind the gastric infusion, and concrete outcome sees Table 2 and table 3:
Table 2: laboratory animal change of blood sugar (0-6W)
Annotate: * represents to compare with model group P＜0.05, and * * represents to compare with model group P＜0.01.
Table 3: laboratory animal change of blood sugar (8-12W)
Annotate: * represents to compare with model group P＜0.05, and * * represents to compare with model group P＜0.01.
Respectively organize blood glucose value and model group after 4 weeks of administration relatively, difference is not obvious; After 6 weeks of administration, bitter cold core group and model group comparing difference are obvious; After 8 weeks of administration, bitter cold group, bitter cold core side group and metformin group and model group compare, obvious difference, and core side's group also has better trend; After 12 weeks of administration, full side group, bitter cold group, bitter cold core group, core side's group, metformin group, rosiglitazone group are than model group downward modulation (P＜0.05).
3.4. Blood Lipid situation (one factor analysis of variance of analytical method: Excel)
Behind the gastric infusion 12W, all rat femoral sacrificed by exsanguination, blood sample collection, separation of serum, adopt respectively free cholesterol (E1006) and triglyceride (GPO-POD enzyme process) kit measurement of Puli's Lay company, adopt kit measurement T-CHOL, low density lipoprotein, LDL and high density lipoprotein, the results are shown in Table 4-table 7:
Table 4: each is organized triglyceride and changes (mean ± SD, unit: mmol/L)
Annotate: * represents to compare with model group P＜0.05, and * * represents to compare with model group P＜0.01.
By as seen from Table 4 after treatment, bitter cold, core side, metformin group and rosiglitazone group triglyceride are more obvious than model group downward modulation.
Table 5: each is organized T-CHOL and changes (mean ± SD, unit: mmol/L)
Annotate: * represents to compare with model group P＜0.05, and * * represents to compare with model group P＜0.01.
By as seen from Table 5 after treatment, turn down comparatively obvious (P＜0.05) under metformin, rosiglitazone group, core side, bitter cold group and the model group comparison T-CHOL.
Table 6: each is organized low density lipoprotein, LDL and changes (mean ± SD unit: mmol/L)
Annotate: * represents to compare with model group P＜0.05, and * * represents to compare with model group P＜0.01.
By as seen from Table 6 through the treatment after, core side, bitter cold group and bitter cold core side group, metformin group and model group comparison low-density lipoprotein cholesterol obviously reduce (P＜0.05).
Table 7: each is organized high density lipoprotein and changes (mean ± SD, unit: mmol/L)
Annotate: * represents to compare with model group P＜0.05, and * * represents to compare with model group P＜0.01.
By as seen from Table 7 through the treatment after, metformin, Clearing heat and removing obstruction of fu-organs, pungent drugs can disperse and bitter drugs can descend group and model group comparison high density lipoprotein obviously raise.
Change (end-point method is measured, μ mol/L) 3.5 respectively organize glycated serum protein
Behind the gastric infusion 12W, all rat fasting 12h, the femoral artery sacrificed by exsanguination, blood sample collection, separation of serum adopts end-point method to measure glycated serum protein by consonance medical university laboratory medicine center (the related assays qualification is arranged).The results are shown in Table 8, full side group, core side, bitter cold group, rosiglitazone group descend comparatively obvious.
Table 8: measure and respectively organize glycated serum protein table (mean ± SD, μ mol/L)
Annotate: * represents to compare with model group P＜0.05, and * * represents to compare with model group P＜0.01.
Change (the RIA method is measured, μ iu/mL) 3.6 respectively organize serum insulin
Behind the gastric infusion 12W, all rat fasting 12h, the femoral artery sacrificed by exsanguination, blood sample collection, separation of serum adopts Millipore company rat insulin radioimmunoassay kits, adopts the R-911 Full automatic to exempt from calculating instrument (Chinese University of Science and Technology's industry head office) and measures rat blood serum insulin level (unit, μ iu/mL), the results are shown in Table 9.The blank group insulin expression of model group descends, and bitter cold group, bitter cold core side, core side compare insulin expression and raise comparatively obvious with model group.
Table 9: measure and respectively organize serum insulin table (mean ± SD, μ iu/mL)
Annotate: * represents to compare with model group P＜0.05, and * * represents to compare with model group P＜0.01.
3.7. pancreas insulin immunohistochemical staining
Pancreatic tissue paraffin section Insulin immunohistochemical staining step (all reagent are DAKO company product):
1) paraffin section dimethylbenzene I, II dewaxing is each 15 minutes, and gradient ethanol namely goes out namely (concentration is respectively 100%, 100%, 95%, 95%, 90%, 80%, 70%, 50%) to water;
2) flowing water embathed 5 minutes;
3) 0.3% H
2O
2Solution oxide 15 minutes;
4) flowing water embathed 5 minutes, and PBS washes 5 minutes * 3 times;
5) drip respectively 1 of suitably dilution: 100Insulin primary antibodie, (establishing simultaneously negative control replaces I to resist with PBS), 4 ℃ of refrigerator overnight incubation;
6) PBS washes 5 minutes * 3 times;
7) drip 1: 400 biotin labeling two and resist, keep somewhere 1.5 hours (room temperature) in the wet box;
8) PBS washes 5 clocks * 3 time;
9) colour developing of DAB solution is 2 minutes;
10) flowing water embathed 5 minutes, and the Mayer hematoxylin was contaminated 1 minute, and rear flowing water embathes,
11) gradient alcohol dehydration (concentration is respectively 50%, 70%, 80%, 90%, 95%, 100%), transparent each 15 minutes of dimethylbenzene I, II;
12) DPX mounting;
The result shows: the immunoreation positive products of expression of insulin is brown yellow granule, exists in the β cell cytoplasm.Normal group insulin stained positive (Fig. 1) β cell is positioned at the islets of langerhans central part, and it is darker to dye, and model group insulin stained positive β cell quantity obviously reduces, and it is more shallow to dye, and is dispersed in distribution.It is different that all treatment groups are improved degree, and wherein core side's group (Fig. 3) is comparatively obvious, and insulin stained positive β cell quantity increases than model group (Fig. 2).Displaing core side has certain islets of langerhans protective effect.
3.8 pancreas Ultrastructural observation
Get each 5 of the fresh pancreatic tissues of rat, be fixed in immediately 2.5% (volume fraction) glutaraldehyde solution, use again 1% (volume fraction) osmic acid to fix.The dehydration of acetone gradient, the Epon812 embedding.Do the ultrathin section color behind the islets of langerhans of semithin section location.JBVI-1230 type transmission electron microscope observing.Referring to Fig. 5-8.
Normal group (Fig. 4): visible volume β cell in the islets of langerhans is full of circular granular of the same size in the kytoplasm.Granule has film to hold, and most of granule has a significantly empty dizzy dense-core that reaches off normal, part granule low electron density, evenly.Golgi complex, mitochondrion and rough endoplasmic reticulum structure are normal; Model group (Fig. 5): the pyknosis of β cell karyon, the agglomerate that differs in size concentrates on the nuclear membrane place, and the kytoplasm endoparticle is sparse, size and skewness.See the volume cavity in the kytoplasm, a large amount of lysosomes; Core side's group (Fig. 6): β cell cytoplasm endoparticle reduces, size and skewness.The free dizzy and off normal dense-core of part granule; Part granule low electron density evenly, is the cavity shape, visible lysosome and lamellar body.
The result shows: consistent with pancreas insulin dyeing ImmunohistochemistryResults Results, core side's group has certain islets of langerhans protective effect.
The experimental result analysis-by-synthesis:
Respectively organize blood glucose value and model group after 4 weeks of administration relatively, difference is not obvious; After 6 weeks of administration, bitter cold core group and model group compare, obvious difference, and core side's group and bitter cold group also have than good symptom of a trend; After 8 weeks of administration, bitter cold group, bitter cold core side group and metformin group and model group compare, obvious difference, and core side's group also has than good symptom of a trend; After 12 weeks of administration, full side group, bitter cold group, bitter cold core group, core side's group, metformin group, rosiglitazone group are reduced than model group, wherein entirely just group, core side's group, bitter cold core group, metformin, the rosiglitazone group is compared with model group has significant difference (P＜0.05).
Clearing heat and removing obstruction of fu-organs and the series side of tearing open thereof have more certain regulating action to blood lipid metabolism.Core side, bitter cold group and bitter cold core side group and model group comparison low-density lipoprotein cholesterol obviously reduce, turn down comparatively obviously under metformin, rosiglitazone group, core side, bitter cold group and the model group comparison T-CHOL, bitter cold group, core side's group, metformin group and full side group triglyceride are more obvious than the model group downward modulation.This may be one of its important function mechanism of intervening diabetes and vascular complication thereof to lipometabolic regulating action.
Each treatment group is compared with model group with full side's group, bitter cold group, bitter cold core group, core side's group, metformin group, rosiglitazone group the Regulation of blood glucose of animal has statistical significance, and this is consistent with clinical effectiveness.And bitter cold group, bitter cold core group and core side's group hypoglycemic effect are suitable with metformin, with approaching of full side's group hypoglycemic effect.Simultaneously, core side's group, bitter cold group and bitter cold core side group adjusting lipid metabolism aspect have obvious advantage.The result is similar with the clinical research in early stage, and full side group has preferably the regulating action to glycolipid metabolism, but dosage is larger.
Pancreas insulin dyeing SABC and the demonstration of pancreas Ultrastructural observation, in these three groups of core side's group, bitter cold group and bitter cold core side groups, core side's group has certain islets of langerhans protective effect, and effect is better than all the other two groups.
Comprehensive blood glucose, blood fat and other experimental result are excellent with core side's group blood sugar lowering and whole structure.
Be specific embodiments of the invention only below, do not limit protection scope of the present invention with this; Any replacement and the improvement done on the basis of not violating the present invention's design all belong to protection scope of the present invention.
Claims (3)
1. a medicine for the treatment of diabetes is characterized in that, its active ingredient is that the crude drug by following weight parts is prepared from: Fructus Momordicae charantiae 25-35 part, Rhizoma Coptidis 25-35 part, Monas cuspurpureus Went 2-4 part, Rhizoma Zingiberis Preparatum 4-8 part, Radix Et Rhizoma Rhei 1-3 part.
2. the medicine for the treatment of diabetes according to claim 1 is characterized in that, its active ingredient is that the crude drug by following weight parts is prepared from: 30 parts in Fructus Momordicae charantiae, 30 parts of Rhizoma Coptidis, 3 parts in Monas cuspurpureus Went, 6 parts of Rhizoma Zingiberis Preparatums, 2 parts of Radix Et Rhizoma Rhei.
3. the medicine for the treatment of diabetes according to claim 1 and 2, it is characterized in that: the dosage form of described medicine is decoction, electuary, pill, capsule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101842408A CN102847095A (en) | 2011-07-01 | 2011-07-01 | Pharmaceutical composition for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101842408A CN102847095A (en) | 2011-07-01 | 2011-07-01 | Pharmaceutical composition for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102847095A true CN102847095A (en) | 2013-01-02 |
Family
ID=47394340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101842408A Pending CN102847095A (en) | 2011-07-01 | 2011-07-01 | Pharmaceutical composition for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102847095A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417950A (en) * | 2013-08-26 | 2013-12-04 | 中国中医科学院广安门医院 | Traditional Chinese medicine composition for preventing and treating obese type 2 diabetes combined dyslipidemia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726929A (en) * | 2004-07-30 | 2006-02-01 | 天津天士力制药股份有限公司 | Compsn. of medication for treating diabetes |
| CN101085079A (en) * | 2007-07-06 | 2007-12-12 | 陈奇 | Traditional Chinese medicine compound for treating diabetes and its preparation method and application |
| CN101204573A (en) * | 2007-12-12 | 2008-06-25 | 中国中医科学院广安门医院 | Medicine foe diabetes mellitus |
-
2011
- 2011-07-01 CN CN2011101842408A patent/CN102847095A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726929A (en) * | 2004-07-30 | 2006-02-01 | 天津天士力制药股份有限公司 | Compsn. of medication for treating diabetes |
| CN101085079A (en) * | 2007-07-06 | 2007-12-12 | 陈奇 | Traditional Chinese medicine compound for treating diabetes and its preparation method and application |
| CN101204573A (en) * | 2007-12-12 | 2008-06-25 | 中国中医科学院广安门医院 | Medicine foe diabetes mellitus |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417950A (en) * | 2013-08-26 | 2013-12-04 | 中国中医科学院广安门医院 | Traditional Chinese medicine composition for preventing and treating obese type 2 diabetes combined dyslipidemia |
| CN103417950B (en) * | 2013-08-26 | 2015-11-25 | 中国中医科学院广安门医院 | A kind of Chinese medicine composition merging dyslipidemia for preventing and treating obese type 2 diabetes mellitus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101357136A (en) | Composition of traditional Chinese medicine effective constituent for preventing and treating diseased associated with cerebral ischemia injury | |
| CN109549971A (en) | A kind of functional food and preparation method thereof adjusting hyperglycemia | |
| CN102133221B (en) | Compound traditional Chinese medicine extract preventing glucose metabolism disturbance and preparation method thereof | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN105030984A (en) | Lychee seed health oral liquid for reducing blood glucose, regulating blood lipid and relieving diabetic complications as well as preparation method of lychee seed health oral liquid | |
| CN101336974B (en) | Traditional Chinese medicine for reducing blood sugar and regulating lipid with overall regulation of body metabolism and preparation method thereof | |
| CN102448479B (en) | A novel antidiabetic furostanolic saponin rich (fsr) fraction from fenugreek seeds | |
| CN101890073B (en) | Chinese medicinal composition for preventing and treating hyperlipaemia and fatty liver and preparation method thereof | |
| CN113730464A (en) | New application of rhizoma coptidis pill, extract and pharmaceutical composition thereof and rhizoma coptidis pill product | |
| CN110876768A (en) | Traditional Chinese medicine formula, preparation method and application for losing weight, reducing fat and reducing blood fat | |
| CN102847095A (en) | Pharmaceutical composition for treating diabetes | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN109223811A (en) | Panaxsaponin composition with hypoglycemic activity | |
| CN102106993B (en) | Chinese medicinal composition for treating fatty liver and preparation method thereof | |
| CN105535152B (en) | Application of loquat leaf total sesquiterpene extract | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN103877323B (en) | Medicinal composition for treating non-alcoholic fatty liver disease | |
| Rahman et al. | Nigella sativa oil potentiates the effects of pioglitazone on long term alloxan-induced diabetic rats | |
| CN108404088B (en) | Traditional Chinese medicine for treating type II diabetes and preparation method thereof | |
| CN101269152A (en) | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament | |
| CN101843763B (en) | Traditional Chinese medicine capable of treating complicated symptom of diabetes and stagnant heat and application thereof | |
| CN102430001B (en) | Compound rose-hip flavone preparation for preventing diabetes mellitus and preparation method thereof | |
| CN101406576B (en) | Chinese medicine for treating diabetes and preparation method | |
| CN1872230B (en) | A medication for treating coronary heart disease and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 510530, No. 32, Po Po Road, Yun Po Industrial Area, Guangzhou, Guangdong, Luogang District Applicant after: Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. Address before: 510530, No. 32, Po Po Road, Yun Po Industrial Area, Guangzhou, Guangdong, Luogang District Applicant before: Guangzhou Zhongyi Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GUANGZHOU ZHONGYI PHARMACEUTICAL CO., LTD. TO: GUANGZHOU BAIYUNSHAN ZHONGYI PHARMACEUTICAL CO., LTD. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130102 |